NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

WHWK

Whitehawk Therapeutics Inc

Jul 02 • 04:00PM ET

1.88

Dollar change +0.02
Percentage change 1.08	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD BMRN RARE ARGX AGIO AFMD AMRN ATRA ADAP VIVS

| Held by: VTI VXF IWC DFAT AVSC

Scroll to Statements

Index	-	P/E	12.53	EPS (ttm)	0.15	Insider Own	44.44%	Shs Outstand	46.78M	Perf Week	0.53%
Market Cap	88.57M	Forward P/E	-	EPS next Y	-1.89	Insider Trans	-0.05%	Shs Float	26.18M	Perf Month	8.05%
Enterprise Value	-142.49M	PEG	1.91	EPS next Q	0.49	Inst Own	45.75%	Short Float	1.09%	Perf Quarter	10.59%
Income	27.61M	P/S	3.19	EPS this Y	107.49%	Inst Trans	18.52%	Short Ratio	2.01	Perf Half Y	-41.43%
Sales	27.77M	P/B	0.40	EPS next Y	-1166.98%	ROA	16.00%	Short Interest	0.29M	Perf YTD	-40.41%
Book/sh	4.74	P/C	0.38	EPS next 5Y	6.57%	ROE	17.69%	52W High	3.81 -50.68%	Perf Year	28.77%
Cash/sh	4.90	P/FCF	-	EPS past 3/5Y	42.52% 22.81%	ROIC	12.45%	52W Low	1.21 55.37%	Perf 3Y	-84.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	185.20% -	Gross Margin	88.72%	Volatility	5.30% 6.86%	Perf 5Y	-90.21%
Dividend TTM	-	EV/Sales	-5.13	EPS Y/Y TTM	106.40%	Oper. Margin	-217.92%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	18.95	Sales Y/Y TTM	16.51%	Profit Margin	99.42%	RSI (14)	49.79	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	18.95	EPS Q/Q	369.77%	SMA20	-2.41%	Beta	0.54	Target Price	2.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	33.48%	SMA50	5.92%	Rel Volume	0.18	Prev Close	1.86
Employees	40	LT Debt/Eq	0.00	Earnings	May 08 AMC	SMA200	-13.77%	Avg Volume	142.26K	Price	1.88
IPO	Aug 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	497.83% -	Trades		Volume	25,278	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-24	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $1.75
Aug-21-24	Downgrade	TD Cowen	Buy → Hold
Aug-21-24	Downgrade	Jefferies	Buy → Hold	$11 → $1.50
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-22	Initiated	Jefferies	Buy	$45
Oct-01-21	Initiated	Cowen	Outperform
Sep-14-21	Initiated	Ladenburg Thalmann	Buy	$51
Sep-08-21	Initiated	Piper Sandler	Overweight	$45

Jun-19-25 08:00AM	Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series (PR Newswire)
Jun-13-25 08:44AM	Implied Volatility Surging for Whitehawk Therapeutics Stock Options (Zacks)
May-28-25 08:00AM	Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference (PR Newswire)
May-21-25 08:00AM	Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit (PR Newswire)
May-08-25 04:05PM	Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
08:00AM	Loading…
Mar-26-25 08:00AM	Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals (PR Newswire)
Mar-19-25 11:52AM	Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript (SeekingAlpha)
Mar-14-25 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update (PR Newswire)
Mar-04-25 04:05PM	Aadi Bioscience Announces Closing of $100 Million PIPE Financing (PR Newswire)
Mar-03-25 08:00AM	Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders (PR Newswire) -10.16%
Feb-24-25 08:00AM	Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference (PR Newswire)
Feb-18-25 08:00AM	Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer (PR Newswire)
Feb-05-25 04:05PM	Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025 (PR Newswire) +6.23%
Dec-21-24 06:31AM	Aadi Biosciences Strategic Agreements and Funding Moves (TipRanks)
Dec-19-24 06:30PM	Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO and $100 Million PIPE Financing (PR Newswire) +46.12%
08:00AM	Loading…
Nov-06-24 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update (PR Newswire) +6.53%
Oct-30-24 04:05PM	Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update (PR Newswire)
Aug-20-24 05:00PM	Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates (PR Newswire)
Aug-07-24 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update (PR Newswire)
Jul-31-24 04:05PM	Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update (PR Newswire)
Jul-05-24 01:07PM	3 Russell 2000 Stocks to Sell in July Before They Crash & Burn (InvestorPlace)
May-29-24 04:05PM	Aadi Bioscience to Participate in the Jefferies Healthcare Conference (PR Newswire) -6.38%
May-23-24 05:30PM	Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) -5.70%
May-09-24 01:52PM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 12:53PM	AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.80%
08:00AM	Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update (PR Newswire)
May-01-24 08:01AM	Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update (PR Newswire)
Apr-09-24 08:00AM	Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-03-24 09:40AM	Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-18-24 09:40AM	Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Loading…
Mar-17-24 08:00AM	Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) (PR Newswire)
Mar-15-24 10:43AM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.85%
Mar-13-24 09:05AM	Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +11.34%
08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update (PR Newswire)
Mar-06-24 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update (PR Newswire)
Mar-05-24 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PR Newswire) -13.35%
Mar-01-24 04:08PM	Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO for the Treatment of Malignant PEComa (PR Newswire) +26.82%
Feb-26-24 04:05PM	Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Jan-26-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (PR Newswire)
Jan-19-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium (PR Newswire)
Dec-15-23 09:14AM	Why Is Aadi Bioscience (AADI) Stock Down 56% Today? (InvestorPlace) -56.42%
Dec-14-23 04:05PM	Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations (PR Newswire)
Nov-08-23 08:46AM	Aadi Bioscience Q3 Loss Per Share Narrows (RTT News)
08:00AM	Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update (PR Newswire)
Nov-06-23 04:05PM	Aadi Bioscience to Participate in Jefferies London Healthcare Conference (PR Newswire)
Nov-01-23 04:05PM	Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update (PR Newswire) +6.48%
Oct-19-23 04:05PM	Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting (PR Newswire)
Oct-12-23 04:05PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Oct-05-23 04:05PM	Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium (PR Newswire)
Oct-03-23 04:05PM	Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (PR Newswire) -6.51%
Oct-02-23 08:00AM	Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer (PR Newswire) -11.16%
Sep-20-23 04:30PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-05-23 08:00AM	Aadi Bioscience to Participate at Upcoming Investor Conferences (PR Newswire) -6.31%
Aug-09-23 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update (PR Newswire) -6.85%
Aug-02-23 08:00AM	Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update (PR Newswire)
May-25-23 05:30PM	Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
May-23-23 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Events (PR Newswire)
May-10-23 08:00AM	Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial (PR Newswire) -16.61%
May-03-23 08:00AM	Aadi Bioscience to Report First Quarter 2023 Results and Operational Update (PR Newswire)
Apr-26-23 04:05PM	Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-14-23 01:00PM	Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-06-23 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 (PR Newswire)
Mar-28-23 08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update (PR Newswire) -5.52%
Mar-27-23 08:00AM	Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors (PR Newswire)
Mar-26-23 02:00PM	Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer (PR Newswire)
Mar-15-23 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update (PR Newswire)
Mar-03-23 08:00AM	Aadi Bioscience Announces Leadership Transition (PR Newswire) -14.51%
Feb-22-23 08:00AM	Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Nov-17-22 08:00AM	Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting (PR Newswire)
Nov-09-22 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update (PR Newswire)
Nov-08-22 04:00PM	Aadi Bioscience Announces Planned Leadership Transition (PR Newswire)
Nov-03-22 08:00AM	Aadi Bioscience to Present at Upcoming Investor Conferences (PR Newswire)
Oct-27-22 08:00AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
Oct-12-22 08:01AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
08:00AM	Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation (PR Newswire)
Sep-22-22 04:01PM	Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing (PR Newswire) +8.06%
Sep-01-22 08:00AM	Aadi Bioscience Announces Participation in Upcoming September Investor Conferences (PR Newswire)
Aug-10-22 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update (PR Newswire)
Aug-04-22 06:21AM	Is Aadi Bioscience, Inc. (NASDAQ:AADI) Popular Amongst Insiders? (Simply Wall St.)
Jul-28-22 08:30AM	Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update (PR Newswire)
Jun-23-22 08:00AM	Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes (GlobeNewswire) +6.00%
Jun-01-22 08:00AM	Aadi Bioscience to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-22 08:00AM	Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications (GlobeNewswire)
May-26-22 05:10PM	Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting (GlobeNewswire) +5.11% +6.88%
May-18-22 07:00AM	Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -7.91%
May-12-22 08:32AM	UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) +9.33%
07:00AM	Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-09-22 08:00AM	Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders (GlobeNewswire) -10.81%
May-04-22 08:00AM	Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO from Centers for Medicare and Medicaid Services (GlobeNewswire)
Apr-28-22 05:07PM	Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 (GlobeNewswire) -5.38%
Apr-18-22 08:00AM	Aadi Bioscience to Participate at the Jefferies Biotech on the Bay Summit (GlobeNewswire) -5.81%
Apr-08-22 01:09PM	Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) (GlobeNewswire)
Apr-01-22 05:13AM	Top Biotech Stocks for Q2 2022 (Investopedia)
Mar-31-22 02:45PM	Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes (GlobeNewswire)
Mar-17-22 07:00AM	Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire) +8.40%
Mar-01-22 07:00AM	Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowens 42nd Annual Health Care Conference (GlobeNewswire)
Feb-25-22 04:41AM	Here's What Aadi Bioscience, Inc.'s (NASDAQ:AADI) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Feb-23-22 07:00AM	Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa (GlobeNewswire)
Jan-04-22 04:30PM	Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire) -7.35%
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)

Whitehawk Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Morristown, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BALL BRYAN	See remarks	Mar 03 '25	Sale	2.35	2,147	5,045	102,853	Mar 04 06:09 PM
Giacobello Scott M.	CHIEF FINANCIAL OFFICER	Mar 03 '25	Sale	2.35	2,806	6,594	23,944	Mar 03 08:38 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	2.35	5,690	13,372	33,429	Mar 03 08:37 PM
Lennon David James	Officer	Mar 03 '25	Proposed Sale	2.35	5,690	13,372		Mar 03 08:36 PM
Giacobello Scott M.	Officer	Mar 03 '25	Proposed Sale	2.35	2,806	6,594		Mar 03 08:34 PM
BALL BRYAN	Officer	Mar 03 '25	Proposed Sale	2.35	2,147	5,045		Mar 03 08:31 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Oct 02 '24	Option Exercise	0.00	32,558	0	32,558	Oct 03 07:03 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Oct 03 '24	Sale	1.94	9,689	18,797	22,869	Oct 03 07:03 PM
Lennon David James	Officer	Oct 03 '24	Proposed Sale	1.94	9,689	18,797		Oct 03 07:01 PM
Desai Neil	EXECUTIVE CHAIRMAN	Sep 03 '24	Sale	1.71	40,000	68,316	1,171,543	Sep 05 05:55 PM
Desai Neil	Officer	Sep 03 '24	Proposed Sale	1.79	120,000	214,416		Sep 03 10:40 AM
Desai Neil	EXECUTIVE CHAIRMAN	Aug 02 '24	Sale	1.41	18,933	26,705	1,217,195	Aug 05 06:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Aug 01 '24	Sale	1.50	15,415	23,055	1,236,128	Aug 05 06:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Aug 05 '24	Sale	1.34	5,652	7,595	1,211,543	Aug 05 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WHWK

Whitehawk Therapeutics Inc

Upgrade your FINVIZ experience